Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Jefferies London Healthcare Conference 2025 Transcript
Zimmer Biomet Holdings, Inc. ( ZBH ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Ivan Tornos - President, CEO & Chairman of the Board Suketu Upadhyay - CFO and Executive VP of Finance, Operations & Supply Chain Conference Call Participants Matthew Taylor - Jefferies LLC, Research Division Presentation Matthew Taylor Jefferies LLC, Research Division All right. Great. Thanks for joining us for our next session here at the Jefferies Healthcare Conference.
Could Zimmer Biomet Stock Be Your Next Buy?
Zimmer Biomet (ZBH) could be a strong choice for your investment portfolio, due to its high cash yield, solid fundamentals, and discounted valuation. Companies like this have the capacity to leverage cash for additional revenue growth or to reward their shareholders through dividends or buybacks.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop
Zimmer Biomet's Q3 EPS beats expectations, but a revenue miss and trimmed outlook send shares sliding in pre-market trading.
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2025 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. ( ZBH ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants David DeMartino - Senior Vice President of Investor Relations Ivan Tornos - President, CEO & Chairman of the Board Suketu Upadhyay - CFO and Executive VP of Finance, Operations & Supply Chain Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Patrick Wood - Morgan Stanley, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Taylor - Jefferies LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Edward Ridley-Day - Rothschild & Co Redburn, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, November 5, 2025.
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Q3 Earnings Surpass Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $1.9 per share, beating the Zacks Consensus Estimate of $1.88 per share. This compares to earnings of $1.74 per share a year ago.
Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?
Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zimmer Biomet Q3 Earnings To Highlight Innovation And Growth - Why I Think It's A Buy
Zimmer Biomet Holdings is rated a BUY, driven by innovation momentum and undervalued valuation despite recent stock underperformance. ZBH's 'Magnificent 7' products, strategic acquisitions like Monogram Technologies, and strong cash flow underpin a compelling medium- to long-term investment thesis. Key risks include acquisition integration, margin pressure, regulatory challenges, and operational disruptions from a failed ERP rollout and ongoing litigation.
The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock
Zimmer Biomet expands its foot & ankle trauma lineup with Gorilla Pilon Fusion & Phantom TTC Trauma Nail launches.
ZBH Receives PMDA Approval in Japan for iTaperloc Complete and iG7
Zimmer Biomet wins early PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology.
